Apoptotic melanoma B16-F1 cells induced by lidamycin could initiate the antitumor immune response in BABL/c mice

Oncology Research

Volumn 23, Issue 1-2, 2016, Pages 79-86

  Yang, Jian Lin ^a   Qin, Ye ^a   Li, Liang ^b   Cao, Chu Yu ^a   Wang, Qing ^a   Li, Qian ^a   Lv, Ya Feng ^a   Wang, Yanlin ^a  

^a CHINA THREE GORGES UNIVERSITY   (China)

^b INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

Author keywords

Calreticulin; Immunogenic cell death; Immunotherapy; Lidamycin (LDM); Melanoma; Mouse

Indexed keywords

ANTIBIOTIC AGENT; CALRETICULIN; CYTOCHROME C; CYTOTOXIC AGENT; ENEDIYNE; GAMMA INTERFERON; LIDAMYCIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AMINOGLYCOSIDE; ANTIBIOTIC C 1027; ANTINEOPLASTIC ANTIBIOTIC; CALB2 PROTEIN, MOUSE; CALRETININ;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER IMMUNIZATION; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL DEATH; CELL MEMBRANE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOMETRY; CYTOSOL; DENDRITIC CELL; DOSE RESPONSE; FEMALE; IMMUNOGENICITY; IMMUNOSTIMULATION; IN VITRO STUDY; INNATE IMMUNITY; MACROPHAGE; MELANOMA; MELANOMA B16; MELANOMA CELL LINE; MITOCHONDRION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTON TRANSPORT; SPLEEN CELL; TUMOR IMMUNITY; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CYTOTOXICITY; DRUG EFFECTS; DRUG SCREENING; IMMUNOLOGY; MELANOMA, EXPERIMENTAL; METABOLISM; PATHOLOGY;

AMINOGLYCOSIDES; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CALBINDIN 2; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; DRUG SCREENING ASSAYS, ANTITUMOR; ENEDIYNES; KILLER CELLS, NATURAL; MELANOMA, EXPERIMENTAL; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; PHAGOCYTOSIS;

EID: 84955483272     PISSN: 09650407     EISSN: 15553906     Source Type: Journal    
DOI: 10.3727/096504015X14478843952942     Document Type: Article

References (28)

1. Obeid, M.; Tesniere, A.; Ghiringhelli, F.; Fimia, G. M.; Apetoh, L.; Perfettini, J. L.; Castedo, M.; Mignot, G.; Panaretakis, T.; Casares, N.; Metivier, D.; Larochette, N.; van Endert, P.; Ciccosanti, F.; Piacentini, M.; Zitvogel, L.; Kroemer, G. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13:54-61; 2007.
2. Obeid, M.; Panaretakis, T.; Joza, N.; Tufi, R.; Tesniere, A.; van Endert, P.; Zitvogel, L.; Kroemer, G. Calreticulin exposure is required for the immunogenicity of γ-irradiation and UVC lightinduced apoptosis. Cell Death Differ. 14:1848-1850; 2007.
3. Cao, C. Y.; Han, Y.; Ren, Y. S.; Wang, Y. L. Mitroxantronemediated apoptotic B16-F1 cells induce specific anti-tumor immune response. Cell. Mol. Immunol. 6:469-475; 2009.
4. Ostwald, T. J.; MacLennan, D. H. Isolation of a high affinity calcium binding protein from sarcoplasmic reticulum. J. Biol. Chem. 249:974-979; 1974.
5. Michalak, M.; Robert Parker, J. M.; Opas, M. Ca2+ signaling and calcium binding chaperones of the endoplasmic reticulum. Cell Calcium 32:269-278; 2002.
6. Gardai, S. J.; McPhillips, K. A.; Frasch, S. C.; Janssen, W. J.; Starefeldt, A.; Murphy-Ullrich, J. E.; Bratton, D. L.; Oldenborg, P. A.; Michalak, M.; Henson, P. M. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 123:321-334; 2005.
7. Lauber, K.; Blumenthal, S. G.; Waibel, M.; Wesselborg, S. Clearance of apoptotic cells: Getting rid of the corpses. Mol. Cell 14:277-287; 2004.
8. Kroemer, G.; Galluzzi, L.; Kepp, O.; Zitvogel, L. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 31:51-72; 2013.
9. Hu, J. L.; Xue, Y. C.; Xie, M. Y.; Zhang, R.; Otani, T.; Minami, Y.; Yamada, Y.; Marunaka, T. A new macromolecular antitumor antibiotic, C-1027. I. Discovery, taxonomy of producing organism, fermentation and biological activity. J. Antibiot. 41:1575-1579; 1988.
10. Otani, T.; Minami, Y.; Marunaka, T.; Zhang, R.; Xie, M. Y. A new macromolecular antitumor antibiotic, C-1027. II. Isolation and physico-chemical properties. J. Antibiot. 41:1580-1585; 1988.
11. Sakata, N.; Ikeno, S.; Hori, M.; Hamada, M.; Otani, T. Cloning and nucleotide sequencing of the antitumor antibiotic C-1027 apoprotein gene. Biosci. Biotechnol. Biochem. 56:1592-1595; 1992.
12. Tanaka, T.; Hirama, M.; Otani, T. Solution structures of C-1027 apoprotein and its complex with the aromatized chromophore. J. Mol. Biol. 309:267-283; 2001.
13. Xu, Y. J.; Zhen, Y. S.; Goldberg, I. H. C-1027 chromophore, a potent new enediyne antitumor antibiotic, induces sequence-specific double-strand DNA cleavage. Biochemistry 33:5947-5954; 1994.
14. Chen, J.; Ou-Yang, Z. G.; Zhang, S. H.; Zhen, Y. S. Downregulation of NF-κB by lidamycin in association with inducing apoptosis in human pancreatic cancer cells and inhibiting xenograft growth. Oncol. Rep. 17:1445-1451; 2007.
15. Zhen, Y. Z.; Lin, Y. J.; Shang, B. Y.; Zhen, Y. S. Enediyne lidamycin induces apoptosis in human multiple myeloma cells through activation of p38 mitogen-activated protein kinase and c-Jun NH2-terminal kinase. Int. J. Hematol. 90:44-51; 2009.
16. Zhang, Q.; Liu, X. J.; Hu, L.; Liao, D. S.; Zheng, Y. B.; Zhen, Y. S.; Song, X. Factor VII light chain targeted lidamycin targets tissue factor-overexpressing tumor cells for cancer therapy. Int. J. Mol. Med. 29:409-415; 2012.
17. Zhen, Y. Z.; Zhao, Y. F.; Luo, G. L.; Zhang, G. L.; Liu, X. J.; Li, R.; Kan, Q. Lidamycin inhibits mouse myeloma SP2/0 in vivo and in vitro. Basic Clin. Med. 33:992-997; 2013.
18. Pledgie-Tracy, A.; Billam, M.; Hacker, A.; Sobolewski, M. D.; Woster, P. M.; Zhang, Z.; Casero, R. A.; Davidson, N. E. The role of the polyamine catabolic enzymes SSAT and SMO in the synergistic effects of standard chemotherapeutic agents with a polyamine analogue in human breast cancer cell lines. Cancer Chemocher. Pharmacol. 65:1067-1081; 2010.
19. Cao, C.; Han, Y.; Ren, Y.; Wang, Y. Apoptotic B16-F1 cells coated with recombinant calreticulin mediated antitumor immune response in mice. Chin. J. Cancer Res. 22:253-259; 2010.
20. Wang, X.; Wu, S. Y.; Zhen, Y. S. Lidamycin inhibits proliferation and induces apoptosis in endothelial cells. Chin. J. Antibiot. 28:605-612; 2003.
21. Chen, J.; Wu, S. Y.; Ou-Yang, Z. G.; Zhen, Y. S. Synergy of gemcitabine and lidamycin associated with NF-κB down regulation in pancreatic carcinoma cells. Acta Pharmacol. Sin. 29:614-619; 2008.
22. Kennedy, D. R.; Beerman, T. A. The radiomimetic enediyne C-1027 induces unusual DNA damage responses to doublestrand breaks. Biochemistry 45:3747-3754; 2006.
23. Liu, X.; He, H.; Feng, Y.; Zhang, M.; Ren, K.; Shao, R. Difference of cell cycle arrests induced by lidamycin in human breast cancer cells. Anticancer Drugs 17:73-79; 2006.
24. McHugh, M. M.; Gawron, L. S.; Matsui, S.; Beerman, T. A. The antitumor enediyne C-1027 alters cell cycle progression and induces chromosomal aberrations and telomere dysfunction. Cancer Res. 65:5344-5351; 2005.
25. Huang, Y. H.; Shang, B. Y.; Zhen, Y. S. Antitumor efficacy of lidamycin on hepatoma and active moiety of its molecule. World J. Gastroenterol. 11:3980-3984; 2005.
26. Brusa, D.; Garetto, S.; Chiorino, G.; Scatolini, M.; Miqliore, E.; Camussi, G.; Matera L. Post-apoptotic tumors are more palatable to dendritic cells and enhance their antigen crosspresentation activity. Vaccine 26:6422-6432; 2008.
27. Qin, Y.; Han, Y.; Cao, C. Y.; Ren, Y. S.; Li, C. H.; Wang, Y. L. Melanoma B16-F1 cells coated with fusion protein of mouse calreticulin and virus G-protein coupled receptor induced the antitumor immune response in Balb/C mice. Cancer Biol. Ther. 11:574-580; 2011.
28. Wu, H. Y.; Han, Y.; Qin, Y.; Cao, C. Y.; Xia, Y.; Liu, C. B.; Wang, Y. L. Whole-cell vaccine coated with recombinant calreticulin enhances activation of dendritic cells and induces tumour-specific immune responses. Oncol. Rep. 29:529-534; 2013.